Investor Relations Home
EyePoint Pharmaceuticals develops tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. We have developed three approved products in either the U.S. or the EU for sustained release delivery of drug utilizing multiple generations of our Durasert™ technology system.
Our lead development product, ILUVIEN® is licensed to Alimera Sciences, Inc. and utilizes the third generation of the Durasert technology. ILUVIEN is marketed in the U.K., Germany and Portugal and has or is pending marketing authorization in 14 other EU countries.
EyePoint Pharmaceuticals’ other two FDA-approved products, Retisert® and Vitrasert®, licensed to Bausch & Lomb, Inc., are implants utilizing earlier generations of our Durasert technology system.
Recent ReleasesView all »
Events & Presentations
May 8, 2018 at 4:30 PM ET
Q3 2018 EyePoint Pharmaceuticals Earnings Conference Call
Computershare Investor Services
P.O. Box 43078
Providence, RI 02940 USA